Cancer - Side effect drugs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cancer - Side effect drugs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who started this subject	5/18/2002 2:28:20 PM
From: John McCarthy	of 57

[2000]-[BNP7787]-[("FDA") has granted fast track designation] SAN ANTONIO, Mar 8, 2000 /PRNewswire via COMTEX/ --BioNumerik Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration ("FDA") has granted fast track designation for the development of the Company's BNP7787 to prevent or decrease the nerve damage associated with paclitaxel, a widely-used anticancer drug in the class known as taxanes. BNP7787 is designed to protect normal healthy cells from the toxicity of various types of chemotherapy, including taxane and platinum based anticancer drugs. BNP7787 also has potential to protect against common toxicities of radiation therapy and is currently undergoing Phase 1 clinical trials at the University of Chicago and Roswell Park Cancer Center in the U.S. and at the Free University Hospital in Europe. Taxane and platinum drugs are administered in the treatment of a variety of common cancers including breast, lung, ovarian and many other tumors. The most widely used taxane and platinum drugs include paclitaxel (Taxol(R)), docetaxel (Taxotere(R)), carboplatin (Paraplatin(R)) and cisplatin (Platinol AQ(R)). The administration of these drugs (particularly their administration in combination) results in serious or life-threatening nerve damage (neurotoxicity) that can interfere with cancer patients' ability to function normally. In more severe cases it can result in paralysis and can be life threatening. Paclitaxel induced nerve damage can be severe enough to cause patients and physicians to stop cancer treatment, thereby limiting the amount of the drug that can be given to control the growth of cancer. Currently, there is no approved drug that is safe and effective in protecting against paclitaxel induced nerve damage. data.intelihealth.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next